Cover Image

AUS Bio Limited:產品平台分析

AUS Bio Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253791
出版日期 內容資訊 英文 21 Pages
Back to Top
AUS Bio Limited:產品平台分析 AUS Bio Limited - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 21 Pages



AUS Bio Limited 是致力於開發各種症狀之治療藥的生物科技企業,現在更特別致力於開發新流感治療藥,護膚與化妝品,青光眼的治療藥,還有第二型糖尿病的治療藥。

本報告提供AUS Bio Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,以及後期階段及中止的計劃等相關資訊。

AUS Bio Limited的基本資料

  • AUS Bio Limited概要
  • 主要資訊
  • 企業資料

AUS Bio Limited:R&D概要

  • 主要的治療範圍

AUS Bio Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

AUS Bio Limited:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

AUS Bio Limited:藥物簡介

  • MD-920G
  • MD-960
  • MD-990
  • MD-2009

AUS Bio Limited:開發平台分析

  • 標的別
  • 各作用機制

AUS Bio Limited:暫停中的計劃

AUS Bio Limited:總公司和子公司的所在地



Product Code: GMDHC06935CDB


Global Markets Direct's, 'AUS Bio Limited - Product Pipeline Review - 2015', provides an overview of the AUS Bio Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AUS Bio Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of AUS Bio Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AUS Bio Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AUS Bio Limited's pipeline products

Reasons to buy

  • Evaluate AUS Bio Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AUS Bio Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AUS Bio Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AUS Bio Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AUS Bio Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AUS Bio Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AUS Bio Limited Snapshot
    • AUS Bio Limited Overview
    • Key Information
    • Key Facts
  • AUS Bio Limited - Research and Development Overview
    • Key Therapeutic Areas
  • AUS Bio Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AUS Bio Limited - Pipeline Products Glance
    • AUS Bio Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • AUS Bio Limited - Drug Profiles
    • MD-2009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MD-920G
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MD-960
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MD-990
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AUS Bio Limited - Pipeline Analysis
    • AUS Bio Limited - Pipeline Products by Target
    • AUS Bio Limited - Pipeline Products by Route of Administration
    • AUS Bio Limited - Pipeline Products by Molecule Type
    • AUS Bio Limited - Pipeline Products by Mechanism of Action
  • AUS Bio Limited - Dormant Projects
  • AUS Bio Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AUS Bio Limited, Key Information
  • AUS Bio Limited, Key Facts
  • AUS Bio Limited - Pipeline by Indication, 2015
  • AUS Bio Limited - Pipeline by Stage of Development, 2015
  • AUS Bio Limited - Monotherapy Products in Pipeline, 2015
  • AUS Bio Limited - Preclinical, 2015
  • AUS Bio Limited - Pipeline by Target, 2015
  • AUS Bio Limited - Pipeline by Route of Administration, 2015
  • AUS Bio Limited - Pipeline by Molecule Type, 2015
  • AUS Bio Limited - Pipeline Products by Mechanism of Action, 2015
  • AUS Bio Limited - Dormant Developmental Projects,2015
  • AUS Bio Limited, Other Locations

List of Figures

  • AUS Bio Limited - Pipeline by Top 10 Indication, 2015
Back to Top